MedTrace Logo

Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study

NCT00342992 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 29133

Last updated 2020-09-09

No results posted yet for this study

Summary

The project is a passive follow-up of the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study cohort. Originally, this was a large, randomized, double-blind, placebo-controlled, 2x2 factorial primary prevention trial testing the effects of alpha-tocopherol and beta-carotene supplementation on cancer incidence and mortality. The study was conducted in Finland as a collaboration between the U.S. National Cancer Institute (NCI) and the National Public Health Institute of Finland. NCI has maintained passive surveillance of the cohort through Finnish national registries, including the cancer registry.

The primary purpose of the ATBC cohort follow-up is to use the existing risk factor data and biological specimens (i.e., serum, whole blood, DNA, red blood cells, and toenails) to test hypotheses relevant to cancer etiology, survival, early detection, and prevention. These data and biospecimens continue to provide an invaluable resource for the study of biochemical, nutritional, genetic, and molecular hypotheses. These analyses are made all the more informative and powerful by the addition of cases identified annually during the follow-up period, and the research benefits from a longer pre-diagnosis period (now over 30 years).

Conditions

Sponsors & Collaborators

  • Finnish Institute for Health and Welfare

    collaborator OTHER_GOV

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Demetrius A Albanes, M.D. · National Cancer Institute (NCI)

Eligibility

Min Age
50 Years
Max Age
69 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-03-03
Primary Completion
2020-09-04
Completion
2020-09-04

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00342992 on ClinicalTrials.gov